Macrovipera lebetina venom proteins (MLV proteins)

Macrovipera lebetina venom proteins represent a complex pharmacological cocktail secreted by the Levantine viper, primarily consisting of snake venom metalloproteinases (SVMPs), serine proteinases, phospholipases A2 (PLA2), and disintegrins (Sanz et al., 2008). These proteins function synergistically to induce rapid immobilization of prey through systemic coagulopathy, hemorrhage, and local tissue necrosis (Nalbantsoy et al., 2012). SVMPs, such as lebetase, are major components that degrade extracellular matrix proteins and basement membranes, leading to vascular leakage (Siigur et al., 2001). Disintegrins like lebestatin and obtustatin specifically target integrin receptors (e.g., alpha-1-beta-1), inhibiting platelet aggregation and angiogenesis, which makes them subjects of interest in anti-cancer research (Marcinkiewicz et al., 2003). In clinical practice, these venom proteins are the primary targets for neutralization by polyvalent or monovalent antivenoms, which utilize purified antibodies to bind and clear the toxins from the circulation (WHO, 2016). The high variability in venom composition across different geographical populations of Macrovipera lebetina poses a significant challenge for the efficacy of standardized antivenom treatments (Gazi et al., 2013).

Other names

Levantine viper venomBlunt-nosed viper venomVipera lebetina venom

Neutralization of toxic enzymatic and non-enzymatic components by specific immunoglobulin fragments (F(ab')2 or Fab) which bind to the toxins and facilitate their clearance or prevent their interaction with physiological substrates.